File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Circulating Epstein-Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung: A potential surrogate marker for monitoring disease

TitleCirculating Epstein-Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung: A potential surrogate marker for monitoring disease
Authors
Issue Date2002
Citation
Clinical Cancer Research, 2002, v. 8, n. 4, p. 986-994 How to Cite?
AbstractPurpose: The purpose of this work was to study the sera of patients with lymphoepithelioma-like carcinoma (LELC) of the lung for circulating EBV DNA. Experimental Design: Prospectively collected serum samples from five female patients with advanced, inoperable LELC of the lung were measured for free circulating EBV DNA using a quantitative PCR technique. EBV-encoded small RNA (EBER)-1 was assayed in serial serum samples of three of the rive patients, either from the start or during the initial phase of chemotherapy/radiotherapy until their terminal event or last follow-up. There was only a single-point sample for analysis in the fourth and fifth patients. Six other patients with LELC of the lung were also retrospectively identified, and their sera were tested for EBER-1 at either the first visit plus the last follow-up visit (n = 2), the first visit only (n = 2), or the last follow-up visit only (n = 2). Results: Prospectively collected serum samples from five patients and retrospectively collected serum samples from two patients who had clinical disease at initial serum measurement showed detectable levels of EBER-1. Retrospectively collected serum samples from four patients with no clinical disease had negative sera. There is consistent correlation between the clinical response to treatment and subsequent clinical course of LELC and serum EBER-1 levels in the three prospective patients with longitudinal serum monitoring. Conclusions: This study shows for the first time that free EBV DNA can be detected in the serum of patients with LELC of the lung and further suggests the feasibility of its use for monitoring response to therapy in advanced cases.
Persistent Identifierhttp://hdl.handle.net/10722/251597
ISSN
2020 Impact Factor: 12.531
2020 SCImago Journal Rankings: 5.427

 

DC FieldValueLanguage
dc.contributor.authorNgan, Roger K.C.-
dc.contributor.authorYip, Timothy T.C.-
dc.contributor.authorCheng, Wai Wai-
dc.contributor.authorChan, John K.C.-
dc.contributor.authorCho, William C.S.-
dc.contributor.authorMa, Victor W.S.-
dc.contributor.authorWan, Kwong Kee-
dc.contributor.authorAu, Siu Kie-
dc.contributor.authorLaw, Chun Key-
dc.contributor.authorLau, Wai Hon-
dc.date.accessioned2018-03-08T05:00:25Z-
dc.date.available2018-03-08T05:00:25Z-
dc.date.issued2002-
dc.identifier.citationClinical Cancer Research, 2002, v. 8, n. 4, p. 986-994-
dc.identifier.issn1078-0432-
dc.identifier.urihttp://hdl.handle.net/10722/251597-
dc.description.abstractPurpose: The purpose of this work was to study the sera of patients with lymphoepithelioma-like carcinoma (LELC) of the lung for circulating EBV DNA. Experimental Design: Prospectively collected serum samples from five female patients with advanced, inoperable LELC of the lung were measured for free circulating EBV DNA using a quantitative PCR technique. EBV-encoded small RNA (EBER)-1 was assayed in serial serum samples of three of the rive patients, either from the start or during the initial phase of chemotherapy/radiotherapy until their terminal event or last follow-up. There was only a single-point sample for analysis in the fourth and fifth patients. Six other patients with LELC of the lung were also retrospectively identified, and their sera were tested for EBER-1 at either the first visit plus the last follow-up visit (n = 2), the first visit only (n = 2), or the last follow-up visit only (n = 2). Results: Prospectively collected serum samples from five patients and retrospectively collected serum samples from two patients who had clinical disease at initial serum measurement showed detectable levels of EBER-1. Retrospectively collected serum samples from four patients with no clinical disease had negative sera. There is consistent correlation between the clinical response to treatment and subsequent clinical course of LELC and serum EBER-1 levels in the three prospective patients with longitudinal serum monitoring. Conclusions: This study shows for the first time that free EBV DNA can be detected in the serum of patients with LELC of the lung and further suggests the feasibility of its use for monitoring response to therapy in advanced cases.-
dc.languageeng-
dc.relation.ispartofClinical Cancer Research-
dc.titleCirculating Epstein-Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung: A potential surrogate marker for monitoring disease-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid11948104-
dc.identifier.scopuseid_2-s2.0-0036554967-
dc.identifier.volume8-
dc.identifier.issue4-
dc.identifier.spage986-
dc.identifier.epage994-
dc.identifier.issnl1078-0432-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats